scholarly journals Budgeting for Agile Product Development

2019 ◽  
Vol 1 (1) ◽  
pp. 2169-2178 ◽  
Author(s):  
Maximilian Vierlboeck ◽  
Kristin Gövert ◽  
Jakob Trauer ◽  
Udo Lindemann
Keyword(s):  
Resource Allocation ◽  
Product Development ◽  
Research And Development ◽  
Comprehensive Approach ◽  
Agile Development ◽  
Continuous Growth ◽  
Value Maximization ◽  
Changing Environments ◽  
Budgeting Process

AbstractRecent reports and predictions indicate a consistent and continuous growth in the field of Research and Development. Such growth leads to increased resource investments, which have to be managed effectively to eventually achieve value maximization. This management is cohesive with budgeting. In changing environments, said effectiveness can be difficult to attain.Agile development is supposed to provide the necessary flexibility for uncertain situations and has recently seen a stark adoption incline. Unfortunately, budgeting and resource allocation have not yet been resolved for agile approaches: a comprehensive research including recent publications showed a lack of models and frameworks for the adoption and application of budgeting with agile development. Due to this lack of a comprehensive approach, as well as limitations and restrictions of existing research, this paper describes the design of a budgeting approach suitable for and compatible with agile product development. The developed solution, the Structured Agile Budgeting Process, provides a holistic and interdisciplinary way to allocate resources while still allowing the flexibility and benefits of agile development.

New Product Development in Malaysia: Does Organizational Background Really Matter?

2014 ◽  
Vol 68 (3) ◽  
Author(s):  
Tan Owee Kowang ◽  
Amran Rasli ◽  
Choi Sang Long
Keyword(s):  
Product Development ◽  
Research And Development ◽  
New Product Development ◽  
New Products ◽  
New Product ◽  
Multinational Companies ◽  
Product Performance ◽  
Survey Questionnaire ◽  
New Product Performance ◽  
Npd Performance

New Product Development (NPD) is vital in assisting Research and Development (R&D) based organizations to adapt to the changes in markets and technology for competitive advantage. Ensuring the success of new products and optimization of new product performance is critical and essential for Research and Development based organizations.  Hence, this study is carried out to explore does organizational background in term of company’s ownership (i.e. local or multinational companies) and operational scales (i.e. number of Research and Development staffs) affect NPD performance of Research and Development companies in Malaysia. In line with this, 8 New Product Development performance attributes were identified from literature review. These attributes were subsequently formulated into a survey questionnaire and responded by 186 respondents. Thereafter, the effect of organizational ownership and operational scale toward NPD performance are examined separately via Independent Sample t-test and Analysis of Variance (ANOVA). Finding from the study revealed that the level of NPD performance in multinational R&D companies is higher than local R&D companies. Findings from this research also implied that NPD performance can be further improved by increasing number of R&D staffs.  

Marketing and Technology: A Strategic Coalignment

1987 ◽  
Vol 51 (3) ◽  
pp. 1-14 ◽  
Author(s):  
Noel Capon ◽  
Rashi Glazer
Keyword(s):  
Resource Allocation ◽  
Technological Change ◽  
Marketing Strategy ◽  
Firm Behavior ◽  
Technology Strategy ◽  
Changing Environments ◽  
Integrating Technology ◽  
Technological Resource ◽  
Optimal Set

The authors present a case for integrating technology and marketing strategy as key elements that affect corporate success in rapidly changing environments. After describing the implications of technological change for firm behavior, the authors propose a framework for developing a technology strategy and introduce the technology portfolio. The technology portfolio serves both as a model for technological resource allocation and as an aid in choosing an optimal set of technologies from a set of feasible alternatives.

scholarly journals Certification as a Service

2020 ◽  
pp. 203-210
Author(s):  
Sebastian Copei ◽  
Manuel Wickert ◽  
Albert Zündorf
Keyword(s):  
Industry 4.0 ◽  
Business Models ◽  
Communication Protocols ◽  
Agile Development ◽  
Time To Market ◽  
Changing Environments ◽  
Regulatory Frameworks ◽  
Energy Domain

Abstract The development of industry 4.0 and smart energy IT-Components relies on highly standardized communication protocols to reach vendor-independent interoperability. In innovative and fast-changing environments, the support of standard protocols increases the time to market significantly. In the energy domain, the business models and the regulatory frameworks will be updated more often than the protocols. Thus agile development and supporting standardized protocols at the same time seems to be an issue. Here we will present a new proposal for standardization and certification processes as well as an architecture for a certification platform. Both will improve the support of agile development in the industry and energy domain.

New development and update on China Bioanalysis Forum

Bioanalysis ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 199-201
Author(s):  
Fan Jin ◽  
Daniel Tang ◽  
Kelly Dong ◽  
Dafang Zhong
Keyword(s):  
Drug Discovery ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Drug Development ◽  
Research And Development ◽  
Continuous Growth ◽  
Contract Research Organization ◽  
Drug Discovery And Development ◽  
Medicine Research ◽  
New Development

This article provides an update on new development of China Bioanalysis Forum (CBF). CBF became a member association of Chinese Pharmaceutical Association (CPA) at the end of 2019. The official ceremony and first scientific symposium were held in Shanghai on 18 September 2020. The president of Chinese Pharmaceutical Association and representatives from industry, Contract Research Organization (CRO), hospitals and academic institutes attended the ceremony. Seven experts in the field gave presentations on various topics including Drug Metabolism and Pharmacokinetics (DMPK) and bioanalytical support in drug discovery and development as well as experience in Traditional Chinese Medicine research. With the continuous growth of research and development in China, it is well acknowledged that bioanalysis provides critical support for new innovative medicines and generic drug development in the region.

scholarly journals WIPO Re:Search—A Platform for Product-Centered Cross-Sector Partnerships for the Elimination of Schistosomiasis

2019 ◽  
Vol 4 (1) ◽  
pp. 11 ◽  
Author(s):  
Callie J. Weber ◽  
Joseph Hargan-Calvopiña ◽  
Katy M. Graef ◽  
Cathyryne K. Manner ◽  
Jennifer Dent
Keyword(s):  
Chronic Disease ◽  
Global Health ◽  
Product Development ◽  
Research And Development ◽  
Mass Drug Administration ◽  
Early Stage ◽  
Neglected Diseases ◽  
Non Profit ◽  
For Profit ◽  
Two Sectors

Schistosomiasis is an acute and chronic disease that affects over 200 million people worldwide, and with over 700 million people estimated to be at risk of contracting this disease, it is a pressing issue in global health. However, research and development (R&D) to develop new approaches to preventing, diagnosing, and treating schistosomiasis has been relatively limited. Praziquantel, a drug developed in the 1970s, is the only agent used in schistosomiasis mass drug administration (MDA) campaigns, indicating a critical need for a diversified therapeutic pipeline. Further, gaps in the vaccine and diagnostic pipelines demonstrate a need for early-stage innovation in all areas of schistosomiasis product R&D. As a platform for public-private partnerships (PPPs), the WIPO Re:Search consortium engages the private sector in early-stage R&D for neglected diseases by forging mutually beneficial collaborations and facilitating the sharing of intellectual property (IP) assets between the for-profit and academic/non-profit sectors. The Consortium connects people, resources, and ideas to fill gaps in neglected disease product development pipelines by leveraging the strengths of these two sectors. Using WIPO Re:Search as an example, this article highlights the opportunities for the PPP model to play a key role in the elimination of schistosomiasis.

Sign in / Sign up

Export Citation Format

Share Document